Clinical Outcomes for the Treatment of Pembrolizumab in Patients With Advanced Gastric Cancer

July 13, 2015
Yung-Jue Bang, MD, PhD

Yung-Jue Bang, MD, PhD, professor of medical oncology, College of Medicine, Seoul National University, president, Biomedical Research Institute, Seoul National University Hospital, discusses the clinical results for the treatment of pembrolizumab in patients with advanced gastric cancer.

The test showed a median survival of 11 months in patients. Bang believes the results are very promising because they have opened the door for future testing and trials on gastric cancer.

Yung-Jue Bang, MD, PhD, professor of medical oncology, College of Medicine, Seoul National University, president, Biomedical Research Institute, Seoul National University Hospital, discusses the clinical results for the treatment of pembrolizumab in patients with advanced gastric cancer.